New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
This facility marks a significant milestone in transforming the global food industr
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
Subscribe To Our Newsletter & Stay Updated